Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C

The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

Inclusion Criteria:

• Males and females, ≥ 18 years of age
• Subjects chronically infected with Hepatitis C virus (HCV) genotype 1,2,3 or 4
• HCV RNA viral load ≥ 10,000 IU/mL
• Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)
• Body Mass Index (BMI) of 18 to 35 kg/m2
• Seronegative for Hepatitis C virus (HIV) and Hepatitis B

Exclusion Criteria:

• Evidence of decompensated liver disease
• Evidence of medical condition contributing to chronic liver disease other than HCV